A clinical study on siddha trial drug saaranai ennai (int&ext)in children having Balakarapan (atopic dermatitis)

An open clinical study on BALA KARAPPAN(ATOPIC DERMATITIS)in children with the evaluation of siddha trial drug SAARANAI ENNAI (int&ext)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/08/015416

Enrollment

Registered

2018-08-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L20-L30- Dermatitis and eczema

Interventions

Intervention1: Saaranai Ennai: 1-2ml of saaranai Ennai twice a day for 21 days internally and external application Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: Itching Erythema Hyperpigmentation Lichenification Oozing Vesicles

Exclusion criteria

Exclusion criteria: Scabies Photo dermatitis Psoriasis Frunculosis Secondary bacterial infection

Design outcomes

Primary

Measure	Time frame
Reduction in EASI score(Eczema area severity index) Reduction in clinical symptoms like Itching oozing Lichenification Photos of the patient before and after treatment for the evidence clinical improvementTimepoint: Nil	—

Secondary

Measure	Time frame
It is assessed by comparing the safety parameters before and after treatmentTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr C Shanmugapriya

Government siddha medical college

dr.shanmugapriyaa@gmail.com9445661808

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026